Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
National Cancer Institute (NCI)
Wake Forest University Health Sciences
University of Wisconsin, Madison
Eli Lilly and Company
National Cancer Institute (NCI)
AstraZeneca
Cedars-Sinai Medical Center
Hoosier Cancer Research Network
MOMA Therapeutics
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
BicycleTx Limited
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Edwards Lifesciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
Eli Lilly and Company
National Cancer Institute (NCI)
Eli Lilly and Company
Nagoya City University
Bristol-Myers Squibb
Revolution Medicines, Inc.
NRG Oncology
USWM, LLC (dba US WorldMeds)
Aarhus University Hospital
Memorial Sloan Kettering Cancer Center
ARTBIO Inc.
AstraZeneca
Rutgers, The State University of New Jersey
Actuate Therapeutics Inc.
Modulation Therapeutics, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pfizer
Incyte Corporation
Mirati Therapeutics Inc.
Hoffmann-La Roche
Erasca, Inc.
AstraZeneca